Get to know John Adlesich and some of his public health accomplishments on healthcare industry trends in 2021: Successful supply chains are becoming a key differentiator and vital part of the care delivery process in ways we have never seen before in health care. Getting it right requires strategic systems thinking around all functions in the organization. Among the topics for boards to consider: Increasing storage and self-distribution. What’s old is new again. We see a trend toward more self-distribution models instead of just-in-time delivery from distributors. This allows organizations to buy in bulk, control distribution and minimize their reliance on items at risk of being depleted. Organizations do not have a limitless supply of capital so this is not a one-size-fits-all procurement strategy, but it may make sense for certain items in the supply chain.

John Adlesich about behavior therapy in 2021: PRT is derived from Applied Behavioral Analysis and uses many of the same principals. However, the therapy strategies are more child-directed than observation-directed. The treatment focuses on pivotal behaviors like communication, social skills, academic skills, and the self-monitoring of behaviors. AutismSpeaks.org indicates that PRT techniques are: Effective for eliminating or redirecting challenging behaviors and promoting socially significant behaviors Can be implemented by trained psychologists, speech therapists, special education teachers, and parents Certifiable through The Koegel Autism Center, although certification is not required Offered in both structured and unstructured formats in six short segments that target language, play, and skill acquisition Implemented for about 25 hours each week A lifestyle as much as a therapy and are designed to complement family routines.

John Adlesich about healthcare industry trends: COVID-19 tops the Biden administration’s priorities and will likely do so for the foreseeable future. Vaccine distribution will dominate the first six months of 2021, with federal effort focused on the expansion of testing, contact tracing, and better public health reporting from states and localities up to the CDC and other federal agencies. Data collection and expanded use of data will be critical to the Biden administration’s ongoing COVID-19 response. The administration proposes funding to states and localities for their public health response infrastructure (including registries, reporting, surveillance, and dashboards). The administration also plans to expand the availability of platforms that ensure patient data security and to expand data use rights to enable use and disclosure for research and surveillance. These actions will accelerate research on effective clinical interventions and treatment pathways, expand patient monitoring, and help public health reporting and tracking vaccine distribution. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich believes that 2021 is an important year for the health industry. COVID-19 focused the nation’s attention on the risks associated with overreliance on overseas markets for critical supplies, drugs, and equipment. As an “easy” answer, some are now calling for manufacturers to produce a plurality of medical products domestically. While added domestic investments and expanded US manufacturing capacity are vital components of a holistic strategy for reliable supply, it will be important to strike a balanced approach—one that includes a domestic strategy, but at its core is about diversifying supply, including raw materials, pharmaceutical ingredients, and finished drugs. Achieving this vision requires a surgical approach, starting with identifying the products that are truly needed in an emergency to ensure there isn’t undue concentration in a single country or region. In our view, that means ensuring three or more global suppliers and at least one US-based source readily available to serve the American people. Assessing risk will require new transparency initiatives, requiring manufacturers of critical products to share vital information with government, including supply sources, centers of manufacturing, redundancy and contingency protocols, etc. And all this new information needs a technology backbone that helps government better track product availability, supply chain performance, and sources of supply to predict potential trouble spots in real time during another emergency.